American College of Surgeons CoC launches national pilot study for ProvenCare Lung Cancer Collaborative

NewsGuard 100/100 Score

A national pilot study that will promote evidence-based evaluation and treatment standards for patients with resectable non small cell lung cancer (NSCLC) was launched yesterday by the Commission on Cancer (CoC) of the American College of Surgeons. The Commission on Cancer National Pilot Study for the ProvenCare® Lung Cancer Collaborative is based on the success of the Geisinger Health System's ProvenCare model, which has significantly increased adherence to evidence-based standards, improved clinical outcomes, and engaged patients as participants in their own care when applied to acute care episodes associated with other disease sites.

This groundbreaking study marks the first time that Geisinger's ProvenCare model has been applied to a population of patients undergoing lung resection for NSCLC. It promotes a specific care pathway of 38 standard elements that will be followed from patients' preoperative to postoperative care by treatment teams at six CoC-accredited institutions:
•Geisinger Health System, Danville, PA
•University of Washington Medical Center, Seattle
•Northshore University Health System, Evanston, IL
•Northwestern University Medical Center, Chicago, IL
•Kern Medical Center, Bakersfield, CA
•Duke Raleigh (NC) Hospital

Treatment team members at each participating institution commit to providing all 38 of the established care pathway steps to ensure that patients receive the highest standard of care. Institutions also must provide resources for a collaborative Web-based data entry process and data abstraction capabilities.

"The 87-year-old Commission on Cancer is well qualified to launch this collaborative study due to its long standing commitment to providing quality cancer care," said David P. Winchester, MD, FACS, Medical Director, American College of Surgeons Cancer Programs. The CoC has accredited close to 1,500 cancer treatment centers throughout the United States, which in turn treat 70 to 80 percent of all cancer patients diagnosed each year. "Furthermore, we are inspired to have Geisinger's ProvenCare model applied in this study because it positions health care providers to use 'best practices' in treating patients. And working with health care providers to deliver quality care has long been the cornerstone of Commission on Cancer activities," Dr. Winchester explained.

Importantly, patients in the study lend their participation to the process by making a commitment to communicate with the members of their surgical team (that is, when they don't understand something, or when asked about current medications); getting their family or loved ones involved in their treatment plan; and completing important care steps outlined to them by their health care providers. Patient engagement is an important element of Geisinger's ProvenCare as research studies have shown that patients have better results when they participate in their own medical care.

The Commission on Cancer National Pilot Study for Expanding Geisinger's ProvenCare Methodologies to the Lung Cancer Collaborative plans to accrue a population of 1,000 patients and run for a minimum of 12 months.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First FDA-approved cellular therapy for metastatic melanoma available in South Florida